Celldex Therapeutics, Inc (CLDX)
Health Care ยท In Vitro & in Vivo Diagnostic Substances
Celldex Therapeutics, Inc (CLDX) is listed on Nasdaq, where its shares have traded since May 15, 1986. SentiSense covers Celldex Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is In Vitro & in Vivo Diagnostic Substances. Anthony Marucci is its chief executive officer. The company reports 198 employees, and its corporate website is www.celldex.com.
About Celldex Therapeutics, Inc
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Latest reported results
Celldex Therapeutics reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 245 institutions reported holding CLDX, with 85.0 million shares worth $3.2 billion in aggregate. The largest reported holders were Wellington Management, BlackRock and Kynam Capital Management. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on CLDX
- CLDX sentiment: whether news and social coverage of Celldex Therapeutics, Inc leans bullish or bearish, and the stories driving it.
- CLDX ownership: all 245 reporting institutions, plus insider and congressional trades.
- CLDX financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Celldex Therapeutics, Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Celldex Therapeutics, Inc do?
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies.
What sector is CLDX in?
SentiSense classifies Celldex Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is In Vitro & in Vivo Diagnostic Substances.
Where does CLDX stock trade?
Celldex Therapeutics, Inc (CLDX) is listed on Nasdaq, where its shares have traded since May 15, 1986.
Who is the CEO of Celldex Therapeutics, Inc?
Anthony Marucci is the chief executive officer of Celldex Therapeutics, Inc.